Olezarsen, an antisense oligonucleotide that targets the mRNA for apolipoprotein C-III, reduced triglycerides (TGs) in patients with severe hypertriglyceridemia (sHTG, TG >500 mg/dL) by 50-72% at 6 months in two double-blinded placebo-controlled randomized clinical trials (RCTs, CORE-TIMI 72a, CORE2-TIMI 72b)....
R. Giugliano, N. Marston, B. Bergmark et al.· European Heart Journal· 0 citations
Patients with heterozygous familial hypercholesterolaemia (HeFH), if untreated or undertreated, are characterised by lifelong exposure to elevated low density lipoprotein cholesterol (LDLc) levels, associated with a markedly increased risk of atherosclerotic cardiovascular disease (ASCVD). Recent surveys, however...
E. Stroes, R. S. Rosenson, R. Santos et al.· European Heart Journal· 0 citations
GAG supplementation reverses the increased trans-endothelial albumin leakage under hyperglycemic conditions by restoring the barrier properties of the endothelial glycocalyx layer in vitro.
L. Broekhuizen, M. C. Meuwese, H. Mooij et al.· 0 citations
Olezarsen reduced triglycerides across the hypertriglyceridemia spectrum, with greater effects in patients on background fibrates, particularly with diabetes, to support potential complementary mechanisms and further investigation of concomitant triglyceride-reducing therapy.
Annabel Z. Wang, V. Alexander, T. Prohaska et al.· Journal of Clinical Lipidolo...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.